Skip to content
Retaspimycin
Retaspimycin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target heat shock protein HSP 90-alpha.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
52 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.02124
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A112
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8017218
Mantle-cell lymphomaD020522C83.1516
Large-cell lymphoma anaplasticD017728C84.6415
Hodgkin diseaseD006689C81325
Breast neoplasmsD001943EFO_0003869C50345
Prostatic neoplasmsD011471C61224
LeukemiaD007938C95314
MelanomaD008545134
Kidney neoplasmsD007680EFO_0003865C64123
Lung neoplasmsD008175C34.90223
Show 12 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451C91.188
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.088
B-cell lymphoma marginal zoneD018442C88.455
Follicular lymphomaD008224C8255
Large b-cell lymphoma diffuseD016403C83.355
Myeloid leukemia acuteD015470C92.044
Adult t-cell leukemia-lymphomaD015459C91.544
Non-hodgkin lymphomaD008228C85.944
Burkitt lymphomaD002051C83.744
Large-cell lymphoma immunoblasticD01640044
Show 29 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRETASPIMYCIN
INNretaspimycin
Description
Retaspimycin is an ansamycin that is tanespimycin in which the benzoquinone moiety has been reduced to the corresponding hydroquinone. A semi-synthetic analogue of geldanamycin, it is used (generally as the hydrochloride salt) in cancer treatment. It has a role as a Hsp90 inhibitor and an antineoplastic agent. It is a member of hydroquinones, an ansamycin, an organic heterobicyclic compound, a secondary amino compound, a semisynthetic derivative and a carbamate ester. It is functionally related to a geldanamycin. It is a conjugate base of a retaspimycin(1+).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=CCNc1c(O)cc2c(O)c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)N2
Identifiers
PDB
CAS-ID857402-23-4
RxCUI
ChEMBL IDCHEMBL1184904
ChEBI ID71975
PubChem CID
DrugBank
UNII IDBZF2ZM0I5Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HSP90AA1
HSP90AA1
Organism
Homo sapiens
Gene name
HSP90AA1
Gene synonyms
HSP90A, HSPC1, HSPCA
NCBI Gene ID
Protein name
heat shock protein HSP 90-alpha
Protein synonyms
epididymis luminal secretory protein 52, epididymis secretory sperm binding protein Li 65p, Heat shock 86 kDa, heat shock 90kD protein 1, alpha, heat shock 90kD protein 1, alpha-like 4, heat shock 90kD protein, alpha-like 4, heat shock 90kDa protein 1, alpha, heat shock protein 90kDa alpha (cytosolic), class A member 1, heat shock protein 90kDa alpha family class A member 1, HSP 86, HSP86, LAP-2, Lipopolysaccharide-associated protein 2, LPS-associated protein 2, Renal carcinoma antigen NY-REN-38
Uniprot ID
Mouse ortholog
Hsp90aa1 (15519)
heat shock protein HSP 90-alpha (P07901)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 244 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details